FDA Approved: ERBITUX — Supplemental Application (ImClone LLC)

View source ↗

Summary

The FDA approved a supplemental application for ERBITUX (cetuximab) submitted by ImClone LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• ERBITUX (cetuximab)

Snippet

SUPPL AP for ERBITUX (CETUXIMAB)